All In Biotech

Drug Trial Radar · NCT01397097

LCS12 vs. ENG Subdermal Implant (Nexplanon) Discontinuation Rate Study

Multicenter, Open-label, Randomized, Controlled Parallel-group Study to Assess Discontinuation Rates, Bleeding Patterns, User Satisfaction and Adverse Event Profile of LCS12 in Comparison to Etonorgestrel Subdermal Implant Over 12 Months of Use in Women 18 to 35 Years of Age

Last checked: Nov 20, 2026Latest source record: Jul 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 766 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

766

Actual

Start

Sep 2011

Primary completion

Jun 2013

Study completion Apr 2015

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jul 19, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to demonstrate that discontinuation rates in women (ages 18-35 years inclusive) using LCS12 are not higher than those seen in women using ENG subdermal implant over a period of 12 months. Secondary objectives are to observe the bleeding patterns, adverse event profiles and the occurrence of unintended pregnancies. Additionally, data on user satisfaction, IUS expulsions and implant site complications will be collected.

Conditions

  • Contraception

Interventions

  • LNG-IUS (BAY 86-5028)Drug

    LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years

  • 68 mg etonorgestrel implant for subdermal use (Nexplanon)Drug

    Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Discontinuation rate by treatment groupTime frame: at 12 months

Locations

43 sites in 6 countries. Site status is shown where the registry gives one.

  • Site not named

    Ashfield, New South Wales, Australia

  • Site not named

    Sydney, New South Wales, Australia

  • Site not named

    North Adelaide, South Australia, Australia

  • Site not named

    Parkville, Victoria, Australia

  • Site not named

    Nedlands, Western Australia, Australia

  • Site not named

    Espoo, Finland

  • Site not named

    Helsinki, Finland

  • Site not named

    Helsinki, Finland

  • Site not named

    Helsinki, Finland

  • Site not named

    Kuopio, Finland

  • Site not named

    Tampere, Finland

  • Site not named

    Tampereen Yliopisto, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Turku, Finland

  • Site not named

    Biarritz, France

  • Site not named

    Bordeaux, France

  • Site not named

    Marseille, France

  • Site not named

    Quetigny, France

  • Site not named

    Reims, France

  • Site not named

    Schiltigheim, France

  • Site not named

    Seclin, France

  • Site not named

    Strasbourg, France

  • Site not named

    Elverum, Norway

  • Site not named

    Haugesund, Norway

  • Site not named

    Ski, Norway

  • Site not named

    Straume, Norway

  • Site not named

    Trondheim, Norway

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Gothenburg, Sweden

  • Site not named

    Linköping, Sweden

  • Site not named

    Luleå, Sweden

  • Site not named

    Malmö, Sweden

  • Site not named

    Malmö, Sweden

  • Site not named

    Örebro, Sweden

  • Site not named

    Stockholm, Sweden

  • Site not named

    Stockholm, Sweden

  • Site not named

    Uppsala, Sweden

  • Site not named

    Liverpool, United Kingdom

  • Site not named

    London, United Kingdom

  • Site not named

    Cambridge, Cambridgeshire, United Kingdom

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.